Simulation of monoclonal antibody pharmacokinetics in humans using a minimal physiologically based model

AAPS Journal

Volumn 16, Issue 5, 2014, Pages 1097-1109

  Li, Linzhong ^a   Gardner, Iain ^a   Dostalek, Miroslav ^b   Jamei, Masoud ^a  

^a CERTARA UK LIMITED   (United Kingdom)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

monoclonal antibody; PBPK; pharmacokinetics; simulation

Indexed keywords

ACTIVIN RECEPTOR LIKE KINASE 1; ADALIMUMAB; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; PF 03446962; UNCLASSIFIED DRUG; FC RECEPTOR; FC RECEPTOR, NEONATAL; HLA ANTIGEN CLASS 1; PF-03446962; PROTEIN BINDING;

ARTICLE; COMPUTER SIMULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG TARGETING; ENDOTHELIUM; FEASIBILITY STUDY; HALF LIFE TIME; HUMAN; MATHEMATICAL COMPUTING; MATHEMATICAL MODEL; MATHEMATICAL PARAMETERS; MATHEMATICAL VARIABLE; MONTE CARLO METHOD; PHARMACOLOGICAL PARAMETERS; PHYSIOLOGICALLY BASED PHARMACOKINETIC MODEL; PROTEIN BINDING; PROTEIN BLOOD LEVEL; BIOLOGICAL MODEL; BLOOD; DOSE CALCULATION; DRUG ADMINISTRATION ROUTE; LYMPH; METABOLIC CLEARANCE RATE; METABOLISM; PERMEABILITY;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; COMPUTER SIMULATION; DRUG ADMINISTRATION ROUTES; DRUG DOSAGE CALCULATIONS; FEASIBILITY STUDIES; HALF-LIFE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNOGLOBULIN G; LYMPH; METABOLIC CLEARANCE RATE; MODELS, BIOLOGICAL; MONTE CARLO METHOD; PERMEABILITY; PROTEIN BINDING; RECEPTORS, FC;

EID: 84908356716     PISSN: None     EISSN: 15507416     Source Type: Journal    
DOI: 10.1208/s12248-014-9640-5     Document Type: Article

References (48)

1. Dostalek M et al. Pharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodies. Clin Pharmacokinet. 2013;52(2):83-124.
2. Nestorov I. Whole body pharmacokinetic models. Clin Pharmacokinet. 2003;42(10):883-908. (Pubitemid 36995260)
3. Covell DG et al. Pharmacokinetics of monoclonal immunoglobulin G1, F(ab′)2, and Fab′ in mice. Cancer Res. 1986;46(8):3969-78. (Pubitemid 16075893)
4. Baxter LT et al. Physiologically based pharmacokinetic model for specific and nonspecific monoclonal antibodies and fragments in normal tissues and human tumor xenografts in nude mice. Cancer Res. 1994;54(6):1517-28. (Pubitemid 24106416)
5. Baxter LT, Zhu H, Mackensen DG, Butler WF, Jain RK. Biodistribution of monoclonal antibodies: scale-up from mouse to human using a physiologically based pharmacokinetic model. Cancer Res. 1995;55(20):12.
6. Rippe B, Haraldsson B. Transport of macromolecules across microvascular walls: the two-pore theory. Physiol Rev. 1994;74(1):163-219. (Pubitemid 24045677)
7. Ferl GZ, Wu AM, DiStefano 3rd JJ. A predictive model of therapeutic monoclonal antibody dynamics and regulation by the neonatal Fc receptor (FcRn). Ann Biomed Eng. 2005;33(11):1640-52. (Pubitemid 41801648)
8. Garg A, Balthasar JP. Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice. J Pharmacokinet Pharmacodyn. 2007;34(5):687-709. (Pubitemid 47477039)
9. Ghetie V, Ward ES. FcRn: the MHC class I-related receptor that is more than an IgG transporter. Immunol Today. 1997;18(12):592-8. (Pubitemid 28012280)
10. Urva SR, Yang VC, Balthasar JP. Physiologically based pharmacokinetic model for T84.66: a monoclonal anti-CEA antibody. J Pharm Sci. 2010;99(3):1582-600.
11. Shah DK, Betts AM. Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human. J Pharmacokinet Pharmacodyn. 2012;39(1):67-86.
12. Cao Y, Jusko WJ. Applications of minimal physiologically-based pharmacokinetic models. J Pharmacokinet Pharmacodyn. 2012;39(6):711-23.
13. Gallo JM et al. Pharmacokinetic model-predicted anticancer drug concentrations in human tumors. Clin Cancer Res. 2004;10(23):8048-58. (Pubitemid 39587546)
14. Rocci Jr ML et al. Prednisolone metabolism and excretion in the isolated perfused rat kidney. Drug Metab Dispos. 1981;9(3):177-82. (Pubitemid 11039409)
15. Fronton L, Pilari S, Huisinga W. Monoclonal antibody disposition: a simplified PBPK model and its implications for the derivation and interpretation of classical compartment models. J Pharmacokinet Pharmacodyn. 2014;41(2):87-107.
16. Cao Y, Balthasar JP, Jusko WJ. Second-generation minimal physiologically-based pharmacokinetic model for monoclonal antibodies. J Pharmacokinet Pharmacodyn. 2013;40(5):597 -607.
17. Jamei M, Dickinson GL, Rostami-Hodjegan A. A framework for assessing inter-individual variability in pharmacokinetics using virtual human populations and integrating general knowledge of physical chemistry, biology, anatomy, physiology and genetics: a tale of 'bottom-up' vs 'top-down' recognition of covariates. Drug Metab Pharmacokinet. 2009;24(1):53-75.
18. Jamei M et al. The Simcyp population-based ADME simulator. Expert Opin Drug Metab Toxicol. 2009;5(2):211-23.
19. Waldmann TA, Strober W. Metabolism of immunoglobulins. Prog Allergy. 1969;13:1-110.
20. Waldmann TA, Terry WD. Familial hypercatabolic hypoproteinemia. A disorder of endogenous catabolism of albumin and immunoglobulin. J Clin Invest. 1990;86(6):2093-8.
21. Rostami-Hodjegan A. Physiologically based pharmacokinetics joined with in vitro-in vivo extrapolation of ADME: a marriage under the arch of systems pharmacology. Clin Pharmacol Ther. 2012;92(1):50-61.
22. Weisman MH et al . Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study. Clin Ther. 2003;25(6):1700-21. (Pubitemid 36801943)
23. den Broeder A et al. A single dose, placebo controlled study of the fully human anti-tumor necrosis factor-alpha antibody adalimumab (D2E7) in patients with rheumatoid arthritis. J Rheumatol. 2002;29(11):2288-98.
24. Luu KT et al. A model-based approach to predicting the human pharmacokinetics of a monoclonal antibody exhibiting targetmediated drug disposition. J Pharmacol Exp Ther. 2012;341(3):702-8.
25. Suzuki T et al. Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR. J Immunol. 2010;184(4):1968-76.
26. Kaymakcalan Z et al. Comparisons of affinities, avidities, and complement activation of adalimumab, in fl iximab, and etanercept in binding to soluble and membrane tumor necrosis factor. Clin Immunol. 2009;131(2):308-16.
27. Olszewski WL et al. Lymph draining from foot joints in rheumatoid arthritis provides insight into local cytokine and chemokine production and transport to lymph nodes. Arthritis Rheum. 2001;44(3):541-9. (Pubitemid 32234612)
28. Stepensky D. Local versus systemic anti-tumour necrosis factoralpha effects of adalimumab in rheumatoid arthritis: pharmacokinetic modelling analysis of interaction between a soluble target and a drug. Clin Pharmacokinet. 2012;51(7):443-55.
29. Li L et al. Incorporating target shedding into a minimal PBPKTMDD model for monoclonal antibodies. CPT Pharmacometrics Syst Pharmacol. 2014;3:e96.
30. Mager DE, Jusko WJ. General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J Pharmacokinet Pharmacodyn. 2001;28(6):507-32. (Pubitemid 34289541)
31. Granger DN, Taylor AE. Permeability of intestinal capillaries to endogenous macromolecules. Am J Physiol. 1980;238(4):H457 -64.
32. Stehle G et al. Plasma protein (albumin) catabolism by the tumor itself-implications for tumor metabolism and the genesis of cachexia. Crit Rev Oncol Hematol. 1997;26(2):77-100. (Pubitemid 27362424)
33. Logan R, Kong A, Krise JP. Evaluating the roles of autophagy and lysosomal trafficking defects in intracellular distributionbased drug-drug interactions involving lysosomes. J Pharm Sci. 2013;102(11):4173-80.
34. Bain PG et al. Effects of intravenous immunoglobulin on muscle weakness and calcium-channel autoantibodies in the Lambert- Eaton myasthenic syndrome. Neurology. 1996;47(3):678-83.
35. Nestorov IA et al. Lumping of whole-body physiologically based pharmacokinetic models. J Pharmacokinet Biopharm. 1998;26(1):21-46. (Pubitemid 28429460)
36. Pilari S, Huisinga W. Lumping of physiologically-based pharmacokinetic models and a mechanistic derivation of classical compartmental models. J Pharmacokinet Pharmacodyn. 2010;37(4):365-405.
37. Richter W et al. Mechanistic determinants of biotherapeutics absorption following SC administration. AAPS J. 2012;14(3):559- 570.
38. Shah DK, Betts AM. Antibody biodistribution coefficients: inferring tissue concentrations of monoclonal antibodies based on the plasma concentrations in several preclinical species and human. MAbs. 2013;5(2).
39. Brian Gurbaxani MD, Gardner IB. Are endosomal trafficking parameters better targets for improving mAb pharmacokinetics than FcRn binding affinity? Mol Immunol. 2013;56(4):660-74.
40. Haigler HT, McKanna JA, Cohen S. Rapid stimulation of pinocytosis in human carcinoma cells A-431 by epidermal growth factor. J Cell Biol. 1979;83(1):82-90. (Pubitemid 10197035)
41. Chen Y, Balthasar JP. Evaluation of a catenary PBPK model for predicting the in vivo disposition of mAbs engineered for highaffinity binding to FcRn. AAPS J. 2012;14(4):850-9.
42. Garg A. Investigation of the role of FcRn in the absorption, distribution, and elimination of monoclonal antibodies. In Department of Pharmaceutical Sciences. 2007. PhD. Faculty of the Graduate School of State University of New York at Buffalo.
43. Chen N, Wang W, Faulty S, Fang Y, Lu P, Hamuro L, Hussain A, Prueksaritanant T. The impact of FcRn on tissue distribution of IgG1 in mice. In: AAPS, San 902 Diego, CA, USA; 2012.
44. Bitonti AJ et al. Pulmonary delivery of an erythropoietin Fc fusion protein in non-human primates through an immunoglobulin transport pathway. Proc Natl Acad Sci U S A. 2004;101(26):9763-8. (Pubitemid 38869310)
45. Dall'Acqua WF et al. Increasing the affinity of a human IgG1 for the neonatal Fc receptor: biological consequences. J Immunol. 2002;169(9):5171-80. (Pubitemid 35217187)
46. Vegh A et al. FcRn overexpression in transgenic mice results in augmented APC activity and robust immune response with increased diversity of induced antibodies. PLoS One. 2012;7(4):e36286.
47. Morell A, Terry WD, Waldmann TA. Metabolic properties of IgG subclasses in man. J Clin Invest. 1970;49(4):673-80.
48. Guyton AC. Textbook of medical physiology. 11th ed. New York: Elsevier; 2006.